{
    "metadata": {
        "input_documents": [
            "A Graph in Graph Learning Framework for Drug Target Interaction Prediction.pdf",
            "DrugMCTS.pdf",
            "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "Recent Developments in GNN for Drug Discovery.pdf"
        ],
        "persona": "PhD Researcher in Computational Biology",
        "job_to_be_done": "Prepare a comprehensive literature review focusing on methodologies, datasets, and performance benchmarks",
        "processing_timestamp": "2025-07-28T07:44:48.565002"
    },
    "extracted_sections": [
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "section_title": "[15] Wu, Z.",
            "importance_rank": 1,
            "page_number": 17
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": "[21] Wu, Z.",
            "importance_rank": 2,
            "page_number": 24
        },
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "section_title": "Figure 4:",
            "importance_rank": 3,
            "page_number": 8
        },
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "section_title": "[59] Wu, Z.",
            "importance_rank": 4,
            "page_number": 20
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": "[124] Tang, J.",
            "importance_rank": 5,
            "page_number": 31
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": " MUV",
            "importance_rank": 6,
            "page_number": 17
        },
        {
            "document": "DrugMCTS.pdf",
            "section_title": "However,",
            "importance_rank": 7,
            "page_number": 1
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": "Benchmark Databases",
            "importance_rank": 8,
            "page_number": 14
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": "Molecule Generation",
            "importance_rank": 9,
            "page_number": 2
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "section_title": "[31] Menden, M. P.",
            "importance_rank": 10,
            "page_number": 25
        }
    ],
    "subsection_analysis": [
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "refined_text": " et al. MoleculeNet: A benchmark for molecular machine learning.",
            "page_number": 17
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": " et al. MoleculeNet: a benchmark for molecular machine learning.",
            "page_number": 24
        },
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "refined_text": " MPG outperforms other methods in the antibacterial properties prediction open task hosted by MIT J-Clinic. Inspired by the impressive performance on molecular properties prediction, we took part in an open task released by MIT J-Clinic recently ( https://www.aicures.mit.edu/tasks ), aiming at predicting antibacterial properties of molecules on  Pseudomonas aeruginosa  datasets, for the treat- ment of secondary infections in patients with COVID-19. Our MPG currently ranks the \ufb01rst with",
            "page_number": 8
        },
        {
            "document": "Learn Molecular Representations from Large Unlabeled Molecules for Drug Discovery.pdf",
            "refined_text": " et al. Moleculenet: a benchmark for molecular machine learning. Chemical science  9 , 513\u2013530 (2018). & Masoudi-Nejad, A. Drug\u2013target interaction prediction via chemogenomic space: learning-based methods. Expert opinion on drug metabolism & toxicology  10",
            "page_number": 20
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": " et al. Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. Journal of Chemical Information and Modeling  54 , 735\u2013743 (2014).",
            "page_number": 31
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": " is a filtered subset of PubChem BioAssay, designed to validate virtual screening techniques and includes 17 benchmark tasks.",
            "page_number": 17
        },
        {
            "document": "DrugMCTS.pdf",
            "refined_text": "when confronted with problems that lie beyond their pre-training knowledge or inherent reasoning abili- ties, such as predicting novel drug-target interactions, their performance may fall short of expectations [2]. As interest grows in applying general-purpose large models to scientific domains, various approaches have been proposed to address the aforementioned limitations. Among them, fine-tuning on domain- specific datasets has become a widely adopted",
            "page_number": 1
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": "In addition to newly developed methodologies, benchmark datasets play a vital role in advancing the field of computational drug discovery. High-quality data is essential for all the tasks ranging from molecular design 14 Table 1: GNN-based models discussed in this review and their characteristics. Each row includes the name of the approach, the main model architecture, the prediction task and the datasets used. The approaches are grouped into different bucket based on their tasks. Methods using pre-training are labeled with  \u266f and methods using few-shot learning are labeled",
            "page_number": 14
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": "An earlier step in developing a drug for a certain disease usually involves the search of enormous amount of molecules to create a small subset of candidates for further laboratory testing. To reduce experimental costs and to produce drug candidates more efficiently, many computational approaches have been devel- oped to generate novel molecules [ 6 ,  7 ,  8 ,",
            "page_number": 2
        },
        {
            "document": "Recent Developments in GNN for Drug Discovery.pdf",
            "refined_text": " et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.",
            "page_number": 25
        }
    ]
}